Ceribell Boosts Revenue 33% on ICU EEG Adoption, Raises Full-Year Guidance
Event summary
- Ceribell reported $28.1M in Q2 2026 revenue, up 33% YoY, driven by new account additions and increased utilization.
- Gross margin improved to 92%, aided by manufacturing cost reductions and tariff refunds.
- Company secured a $60M credit facility in August 2026 to refinance existing debt.
- Received multiple FDA 510(k) clearances for new hardware designs and algorithms.
- Raised full-year revenue guidance to $114M–$117M, up from prior $98M–$103M.
The big picture
Ceribell's Q2 results highlight accelerating adoption of its EEG monitoring systems in ICU settings, positioning it as a key player in transforming neurological diagnostics. The company's strategic focus on FDA clearances and manufacturing optimization underscores its push to establish EEG as a standard vital sign, competing directly with Natus Medical Incorporated.
What we're watching
- Revenue Growth Sustainability
- Whether Ceribell can maintain its 33% YoY revenue growth amid seasonal ICU census moderation.
- Regulatory Momentum
- The pace at which FDA clearances for new hardware and algorithms will accelerate product pipeline expansion.
- Operational Efficiency
- How manufacturing cost reductions in Vietnam will impact long-term gross margins.